Show simple item record

dc.contributor.authorPereira Junior, José Carlos
dc.contributor.authorPradella-Hallinan, Márcia Lurdes de Cássia [UNIFESP]
dc.contributor.authorAlves, Rosana Cardoso
dc.date.accessioned2015-06-14T13:45:23Z
dc.date.available2015-06-14T13:45:23Z
dc.date.issued2013-04-01
dc.identifierhttp://dx.doi.org/10.6061/clinics/2013(04)06
dc.identifier.citationClinics. Faculdade de Medicina / USP, v. 68, n. 4, p. 469-474, 2013.
dc.identifier.issn1807-5932
dc.identifier.urihttp://repositorio.unifesp.br/handle/11600/7715
dc.description.abstractOBJECTIVE: Certain drug classes alleviate the symptoms of Willis-Ekbom's disease, whereas others aggravate them. The pharmacological profiles of these drugs suggest that drugs that alleviate Willis-Ekbom's disease inhibit thyroid hormone activity, whereas drugs that aggravate Willis-Ekbom's disease increase thyroid hormone activity. These different effects may be secondary to the opposing actions that drugs have on the CYP4503A4 enzyme isoform. Drugs that worsen the symptoms of the Willis-Ekbom's disease inhibit the CYP4503A4 isoform, and drugs that ameliorate the symptoms induce CYP4503A4. The aim of this study is to determine whether Saint John's wort, as an inducer of the CYP4503A4 isoform, diminishes the severity of Willis-Ekbom's disease symptoms by increasing the metabolism of thyroid hormone in treated patients. METHODS: In an open-label pilot trial, we treated 21 Willis-Ekbom's disease patients with a concentrated extract of Saint John's wort at a daily dose of 300 mg over the course of three months. RESULTS: Saint John's wort reduced the severity of Willis-Ekbom's disease symptoms in 17 of the 21 patients. CONCLUSION: Results of this trial suggest that Saint John's wort may benefit some Willis-Ekbom's disease patients. However, as this trial was not placebo-controlled, the extent to which Saint John's wort is effective as a Willis-Ekbom's disease treatment will depend on future, blinded placebo-controlled studies.en
dc.format.extent469-474
dc.language.isoeng
dc.publisherFaculdade de Medicina / USP
dc.relation.ispartofClinics
dc.rightsAcesso aberto
dc.subjectWillis-Ekbom's Diseaseen
dc.subjectRestless Legs Syndrome Treatmenten
dc.subjectRestless Legs Syndromeen
dc.subjectSaint John's Worten
dc.subjectThyroid Hormoneen
dc.subjectCYP4503A4en
dc.titleSaint John's wort, an herbal inducer of the cytochrome P4503A4 isoform, may alleviate symptoms of Willis-Ekbom's diseaseen
dc.typeArtigo
dc.contributor.institutionFaculdade de Medicina de Jundiaí Pediatria
dc.contributor.institutionUniversidade Federal de São Paulo (UNIFESP)
dc.contributor.institutionUniversidade de São Paulo (USP)
dc.description.affiliationFaculdade de Medicina de Jundiaí Pediatria
dc.description.affiliationUniversidade Federal de São Paulo (UNIFESP) Departamento de Psicobiologia
dc.description.affiliationUniversidade de São Paulo Faculdade de Medicina Hospital das Clínicas
dc.description.affiliationUnifespUNIFESP, Depto. de Psicobiologia
dc.identifier.fileS1807-59322013000400469.pdf
dc.identifier.scieloS1807-59322013000400469
dc.identifier.doi10.6061/clinics/2013(04)06
dc.description.sourceSciELO
dc.identifier.wosWOS:000320002000006


Files in this item

This item appears in the following Collection(s)

Show simple item record